



### REMARKS

In response to the Restriction Requirement in the Office Action dated May 3, 2005, Applicants, through and by their representative, elect the claims of Invention II, claims 15-21, drawn to a composition comprising a fused or chimeric polypeptide comprising a first segment capable of binding to at least one of  $\alpha 6\beta 1$  integrin receptor and  $\alpha 6\beta 4$  integrin receptor and a second component chemically bound to the first component, for examination on the merits. Accordingly, Applicants have canceled claims 1-14 as directed to a non-elected invention.

In response to the requirement to elect a single specific second component chemically bound to the first polypeptide component of claim 15, Applicants elect the polypeptide agent IL-2. As such, claim 17, and new claims 50, 53, and 56 directed to a non-protein second component are withdrawn as being directed to a non-elected species.

Applicants further submit that claims 15, 16, 19-21, 43-49, 51, 52, 54, and 55 are generic to these species elections, and as such Applicants request allowance of dependent claims directed to non-elected species should any independent generic claims be held allowable.

Examiner Haddad is invited and encouraged to telephone the undersigned at his convenience should he have any questions with regard to this application.

Please charge any additional fees required by this Response to Deposit Account No. 04-1403.

Respectfully submitted,

DORITY & MANNING, P.A.

5/16/05

BY:

  
Christina L. Mangelsen, Patent Agent  
Registration No. 50,244  
DORITY & MANNING, P.A.  
P.O. Box 1449  
Greenville, SC 29602-1449  
(864) 271-1592